Atai''s New MDMA-Based EMP-01 Compound Moves Forward To The Clinical Stage
Atai Life Sciences'' (NASDAQ: ATAI ) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01 , designed to treat PTSD and other mental health conditions. The randomized, double-blind, placebo-controlled study intends to evaluate the safety and tolerability of single-ascending oral doses of EMP-01 in 32 healthy adult participants, as well as to assess the usability and acceptability of the IDEA-1 app in delivering “set and setting” content to participants in preparation for the drug administration. The research , of which results are expected by the second half of 2023, will include a range of behavioral assessments that, together with the pharmacokinetics and safety … Full story available on Benzinga.com
Atai''s New MDMA-Based EMP-01 Compound Moves Forward To The Clinical Stage
Atai Life Sciences'' (NASDAQ: ATAI ) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01 , designed to treat PTSD and other mental health conditions. The randomized, double-blind, placebo-controlled study intends to evaluate the safety and tolerability of single-ascending oral doses of EMP-01 in 32 healthy adult participants, as well as to assess the usability and acceptability of the IDEA-1 app in delivering “set and setting” content to participants in preparation for the drug administration. The research , of which results are expected by the second half of 2023, will include a range of behavioral assessments that, together with the pharmacokinetics and safety … Full story available on Benzinga.com